URGENT Levomepromazine 25mg/ml injection supply issue – information for Primary Care

URGENT Levomepromazine 25mg/ml injection supply issue – information for Primary Care   Overview of Supply Sanofi informed NHS England and DHSC on 5th April 2019 that they are going out of stock this week of levomepromazine 25mg/ml injection and new stock is expected to be available from the end of April. The supply issue is due to a quality deviation experienced at their Italian factory and is not linked to EU exit. The only other UK supplier, Wockhardt, have informed us that due to the unexpected increase in demand, they will also go out of stock of levomepromazine injection and their next delivery has been delayed with further stock expected at the end of April. Wockhardt have confirmed the remaining levomepromazine 25mg/mL injection stock which is held at Alliance will be ring-fenced for primary care use only. Stock at Alliance is limited and will not last until the end of April. Existing stocks are likely to be exhausted by end of this week and no new supplies are expected until end of April. GPs, palliative care networks and community pharmacies should consider the following advice and work together during this period to ensure patients can be managed appropriately.   Alternative agents UK Medicines Information with support of national clinical specialists have developed the following clinical information to help support the management of patients  who may be affected by this issue. Please follow the link to view this guidance:https://www.sps.nhs.uk/articles/shortage-of-levomepromazine-hydrochloride-25mg-ml-solution-for-injection/ All the suppliers of the following medicines have  been made aware of this supply issue and have confirmed they can support an increase in demand should this be required. Haloperidol 5mg/1ml...

MPS statement on indemnity

MPS have shared a statement with us this morning confirming their arrangements for the coming year following our contract negotiations in England and the changes being worked on in Wales.  This can be shared more widely.   Simon Kayll, MPS Chief Executive said: “Medical Protection has set new subscription fees for general practice members in England and Wales. Most members can expect to receive a significant reduction and in some cases they may be eligible for a partial refund on their current year’s subscription. Medical Protection members will receive a personalised letter setting out their new tailored subscription information in detail in the next couple of days. “The new state-backed scheme won’t protect GPs in all circumstances. This means Medical Protection membership will remain vital to protect against many challenges including regulatory issues, a complaint from a patient or a clinical negligence claim arising from private or fee paying work. “A GP’s subscription will depend on a number of factors including the amount of private or fee paying work they undertake and the number of sessions they work. As an illustration, a GP working eight sessions can expect their subscription to be less than £800. This subscription includes advice and support with medicolegal issues from their NHS and private work as well as our  24 hour medicolegal advice line and risk management support. “If a member carries out fee paying or private work they would need to add protection for any claims that may arise from this activity. The cost of this additional claims protection is dependent on their earnings from private or fee paying work. GPs can earn...